Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eli Lilly

771.39
-9.2800-1.19%
Volume:1.72M
Turnover:1.32B
Market Cap:731.07B
PE:62.77
High:781.15
Open:779.68
Low:762.40
Close:780.67
Loading ...

Eli Lilly Unveils Promising Phase 1 Data for New FRα Targeting ADC in Platinum-Resistant Ovarian Cancer at 2025 ASCO Annual Meeting

Reuters
·
02 Jun

Eli Lilly and Co - Preliminary Orr of 55% at 4 Mg/Kg Dose

THOMSON REUTERS
·
02 Jun

Lilly Presents First Clinical Data for Its Investigational, Next-Generation FrΑ Targeting ADC in Platinum-Resistant Ovarian Cancer at the 2025 Asco Annual Meeting

THOMSON REUTERS
·
02 Jun

Kymera Stock Jumps. New Dermatitis Pill Could Challenge Regeneron Blockbuster. -- Barrons.com

Dow Jones
·
02 Jun

GrÜNenthal: Financial Terms of Transaction Are Not Disclosed

THOMSON REUTERS
·
02 Jun

Could Viking Therapeutics Become the Next Eli Lilly?

Motley Fool
·
02 Jun

BRIEF-Nxera Pharma Co Ltd - Nxera Pharma Achieves Development Milestone In Collaboration With Eli Lilly Targeting Metabolic Diseases

Reuters
·
02 Jun

Nxera Pharma Co Ltd: Nxera Pharma Achieves Development Milestone in Collaboration With Eli Lilly Targeting Metabolic Diseases

THOMSON REUTERS
·
02 Jun

Nxera Pharma Co Ltd: Under Terms of Agreement, Nxera Is Eligible to Receive Development and Commercial Milestones Totalling up to US$694 Mln, Plus Tiered Royalties on Global Sales

THOMSON REUTERS
·
02 Jun

New Hope for Strokes And Heart Attacks -- Barron's

Dow Jones
·
31 May

Eli Lilly & Co. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
31 May

BMO Capital Markets Reiterates ‘Buy’ Rating on Eli Lilly Stock (LLY)

TIPRANKS
·
31 May

Eli Lilly (LLY) Bulls Eye $1,000 Stock Price Target as GLP-1 Alpha Bandwagon Rolls On

TIPRANKS
·
30 May

Eli Lilly Unveils Promising Results from Diabetes and Obesity Trials at ADA's 85th Scientific Sessions

Reuters
·
30 May

Lilly Announces Details of Presentations at American Diabetes Association's (Ada) 85TH Scientific Sessions

THOMSON REUTERS
·
30 May

BRIEF-FDA Approves Labelling Changes For Trulicity, Saxenda & Xultophy 100/3.6 To Include ‘Alopecia’ & ‘Dysesthesia’

Reuters
·
30 May

US FDA Approves Labelling Changes for Trulicity, Saxenda & Xultophy 100/3.6 to Include ‘Alopecia’ & ‘Dysesthesia’ in Letters Dated May 28 - Website

THOMSON REUTERS
·
30 May

Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin. -- Barrons.com

Dow Jones
·
30 May

UBS Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

TIPRANKS
·
30 May

Eli Lilly, Apollo Clinic Partner to Drive Obesity, Type 2 Diabetes Awareness in India - Statement

THOMSON REUTERS
·
29 May